Biomarkers like circulating cell-free DNA, TARC (Thymus and Activation Regulated Chemokine), and total metabolic tumor volume have demonstrated prognostic or predictive value in prior studies, and they should be further explored in randomized trials of PD-1 inhibitor regimens. The gene discussed is CCL17; the disease is neoplasm.